BlossomHill Therapeutics, Inc.

BlossomHill Therapeutics, Inc.

is a clinical-stage biopharmaceutical company based in San Diego, California. Founded in 2020, the company focuses on discovering and developing small-molecule drugs aimed at addressing unmet medical needs in oncology and autoimmune disorders. The founders, Dr. J. Jean Cui and Dr. Y. Peter Li, bring extensive expertise in drug design and development, with a history of successful FDA-approved treatments. The company is advancing several clinical-stage drug candidates, including BH-30643, which targets EGFR mutations in non-small cell lung cancer, and BH-30236, aimed at RNA splicing abnormalities in hematologic malignancies. BlossomHill employs innovative approaches such as kinase inhibition and RNA splicing modulation to create precision medicines that enhance therapeutic efficacy while minimizing side effects. With significant funding and a strong focus on overcoming treatment resistance, BlossomHill is positioned to make a meaningful impact in the biopharmaceutical industry.